

# Wolfgang M Brueckl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5764541/publications.pdf>

Version: 2024-02-01

15  
papers

318  
citations

932766

10  
h-index

996533

15  
g-index

16  
all docs

16  
docs citations

16  
times ranked

447  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). <i>BMC Cancer</i> , 2020, 20, 1185.	1.1	75
2	C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study. <i>Cancers</i> , 2020, 12, 2319.	1.7	52
3	Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient. <i>Lung Cancer</i> , 2016, 95, 35-38.	0.9	31
4	Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492095135.	0.6	24
5	Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. <i>Translational Lung Cancer Research</i> , 2021, 10, 3093-3105.	1.3	23
6	Prognostic and predictive value of estrogen receptor 1 expression in completely resected non-small cell lung cancer. <i>International Journal of Cancer</i> , 2013, 133, 1825-1831.	2.3	20
7	Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer <sup>®</sup> Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 6771-6778.	0.5	20
8	SNAI2/SLUG and estrogen receptor mRNA expression are inversely correlated and prognostic of patient outcome in metastatic non-small cell lung cancer. <i>BMC Cancer</i> , 2015, 15, 300.	1.1	19
9	The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. <i>European Journal of Cancer</i> , 2022, 170, 106-118.	1.3	15
10	Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice – results from the ElderTac study. <i>BMC Cancer</i> , 2018, 18, 333.	1.1	10
11	Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110123.	1.4	8
12	Treatment choice in EGFR-mutant non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2017, 18, 1425-1426.	5.1	6
13	Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP). <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210853.	1.4	6
14	A nomogram to predict the recurrence-free survival and analyze the utility of chemotherapy in stage IB non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 75-86.	1.3	5
15	Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2021, 10, 4106-4119.	1.3	4